Search

Displaying results 1 - 10 of 12 in total
DrugBest match

Ticagrelor

go.drugbank.com/drugs/DB08816
ApprovedInvestigational

Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y12 receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU, . Ticagrelor was granted EMA appr...

  1. Pathway

    Ticagrelor Action Pathway

    smpdb.ca/view/SMP0126465
    Drug action

    Ticagrelor also known via brand names Brilinta or Brilique, is a platelet inhibitor used to prevent infarction, stroke or cardiovascular death. … Grapefruit products should be avoided as it inhibits the CYP3A4 metabolism of ticagrelor and cause an increase in the drug which may lead to an overdose.

    Drugs: Calcium · Magnesium cation · Cyclic adenosine monophosphate · Ticagrelor
  2. Pathway

    Ticagrelor Predicted Metabolism Pathway

    smpdb.ca/view/SMP0174847
    Metabolic

    Metabolites of Ticagrelor are predicted with biotransformer.

    Drugs: Mesoheme · Ticagrelor
  3. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

    Products: TICAGRELOR EG, TICAGRELOR KRKA
  4. Indication

    Thrombosis (Stent Thrombosis)

    go.drugbank.com/conditions/DBCOND0048360
    Drugs: Cangrelor · Ticagrelor · Ticlopidine
  5. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  6. Drug

    Bentracimab

    go.drugbank.com/drugs/DB16659
    Investigational

    Bentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or

  7. Indication

    Cardiovascular Mortality

    go.drugbank.com/conditions/DBCOND0040959
    Drugs: Acetylsalicylic acid · Canagliflozin · Colchicine · Dapagliflozin · Empagliflozin · Evolocumab +12 more
  8. Indication

    Myocardial Infarction

    go.drugbank.com/conditions/DBCOND0027900
    Drugs: Acetylsalicylic acid · Alirocumab · Atenolol · Atorvastatin · Bempedoic acid · Colchicine +13 more
  9. Indication

    Stroke

    go.drugbank.com/conditions/DBCOND0020609
    Drugs: Acetylsalicylic acid · Alirocumab · Apixaban · Atorvastatin · Cerebrolysin · Choline alfoscerate +14 more